https://www.live-feeds.com/feed/astrazeneca-breast-cancer-drug-misses-goal-in-late-stage-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/astrazeneca-breast-cancer-drug-misses-goal-in-late-stage-trialhttps://www.live-feeds.com/feed/astrazeneca-breast-cancer-drug-misses-goal-in-late-stage-trial#u70011Wed, 16 Sep 2026 08:15:19 +0000AstraZeneca PLC stated that its breast cancer pill Etcamah, also known as camizestrant, failed to meet the primary endpoint in the Phase III SERENA-4 trial. The trial tested the drug in combination with Pfizer's palbociclib as a first-line treatment for advanced ER-positive breast cancer. The stumble represents a significant setback for the pharmaceutical company's oncology pipeline. Market analysts suggest that missing this target could potentially reduce future sales projections by billions of dollars, adding to a history of setbacks for oral selective estrogen receptor degraders.W